PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : F

Records returned : 105 (on 24 Nov 2024 at 00:24:17).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Factor VIIa (Recombinant)
No Information Returned
Factor VIII Inhibitor Bypass Fraction
No Information Returned
Factor XIII (Recombinant)
No Information Returned
Famciclovir
No Information Returned
01.03.01
Famotidine
Acid suppression (Adults)
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
10.02.01
Fampridine
Multiple sclerosis
Red
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centre only
Commissioned by NHSE from specialist centres only.
10.01.04
Febuxostat
Hyperuricaemia and Gout
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
For patients where allopurinol is not tolerated or contraindicated
04.08.01
Felbamate
Epilepsy
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
10.03.02
Felbinac
Osteoarthritis
Non Formulary
Formulations :
  • Gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Felodipine
No Information Returned
Fenbufen
No Information Returned
02.12.00
Fenofibrate
Lipid modification
Blue
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Primary care prescribing on recommendation from specialist team for Familial hypercholesterolaemia and hypertriglyceridaemia.
Fenofibrate/simvastatin
No Information Returned
Fenoprofen
No Information Returned
Fenoterol hydrobromide
No Information Returned
04.07.02
Fentanyl
Pain
Blue
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
Prescribe by brand. Not for use in opioid naïve patients. Limited place in therapy - on specialist advice only
04.07.02
Fentanyl
Pain
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
See separate listing for use in assisted ventilation and anaesthesia
04.07.02
Fentanyl
Pain
Red
Formulations :
  • Injection
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Un
Important
100mcg in 2ml injection used intranasally in paediatrics for painful procedures.
04.07.02
Fentanyl
Pain
Non Formulary
Formulations :
  • Buccal tablets
  • Buccal/sublingual
  • Nasal spray
  • Sublingual tablets
  • Lozenges
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
CD
Important
Immediate release fentanyl preparations are non-formulary for all pain indications EXCEPT for breakthrough pain in patients receiving opioid therapy for cancer pain.
Fentanyl citrate
No Information Returned
Fenticonazole nitrate
No Information Returned
Ferric chloride
No Information Returned
Ferric maltol
No Information Returned
Ferrous calcium citrate
No Information Returned
Ferrous fumarate
No Information Returned
Ferrous gluconate
No Information Returned
Ferrous glycine sulfate
No Information Returned
Ferrous sulfate
No Information Returned
Ferumoxytol
No Information Returned
07.04.02
Fesoterodine fumarate
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
3rd line - for patients requiring more potent treatment
Fexofenadine hydrochloride
No Information Returned
05.01.07
Fidaxomicin
Clostridioides difficile
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Granules (for oral suspension) should be used in patients requiring a liquid preparation. Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. For any patient requiring a liquid preparation, fidaxomicin granules should be prescribed. The APC notes that although current NICE guidelines recommend vancomycin first line, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.
01.05.03
10.01.03
Filgotinib
Inflammatory bowel disease
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative colitis - adults only
01.05.03
10.01.03
Filgotinib
Rheumatoid arthritis
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
SA
ICB
BlueTeq
NICE
Filgrastim
No Information Returned
06.04.02
Finasteride
Transgender Health - adults
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
08.02.04
Fingolimod
Multiple sclerosis
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NHSE
BlueTeq
NICE
07.04.02
Flavoxate hydrochloride
Overactive bladder (adults)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
02.03.02
Flecainide acetate
Arrhythmias
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Specialist initiation and at least one month supply before transfer to primary care
02.03.02
Flecainide acetate
Arrhythmias
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Unlicensed. For use or advice by cardiology consultants only.
Flubiprofen
No Information Returned
Flucloxacillin magnesium
No Information Returned
05.01.01
Flucloxacillin sodium
Bacterial infection
Green
Formulations :
  • Capsules
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Contra-indicated in Penicillin Allergy. Follow local guidelines on the use of antimicrobials.
05.01.01
Flucloxacillin sodium
Bacterial infection
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Contra-indicated in Penicillin Allergy. Follow local guidelines on the use of antimicrobials.
Fluconazole
No Information Returned
Fludarabine phosphate
No Information Returned
06.03.01
06.03.02
Fludrocortisone acetate
Orthostatic hypotension
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
Un
NICE
Important
Postural hypotension - off label use. Specialist team initiation and supply for at least 1 month before transfer of prescribing to primary care.
Fludroxycortide
No Information Returned
Flumazenil
No Information Returned
Flumetasone pivalate
No Information Returned
04.06.00
04.07.04
Flunarizine dihydrochloride
Migraine (prevention)
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
U
Important
Restricted to use in patients who are intolerant or refractory to other treatment options
Flunisolide
No Information Returned
Flunitrazepam
No Information Returned
11.04.01
13.04.00
Fluocinolone acetonide
Uveitis
Red
Formulations :
  • Intravitreal implant
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only.
11.04.01
13.04.00
Fluocinolone acetonide
Diabetic macular oedema
Red
Formulations :
  • Intravitreal implant
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
R
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only. In patients who have failed to respond to prior treatments.
Fluocinonide
No Information Returned
Fluocortolone
No Information Returned
11.08.02
Fluorescein sodium
Detection of lesions and foreign bodies
Red
Formulations :
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
11.07.00
Fluorescein with lidocaine
Local anaesthesia (eye)
Red
Formulations :
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Lidocaine 4% with Fluorescein 0.25%
11.04.01
Fluorometholone
Eye inflammation
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Short-term use only. Primary Care prescribing on specialist recommendation.
Fluorouracil (Antimetabolites)
No Information Returned
Fluorouracil (Sunscreen)
No Information Returned
Fluoxetine hydrochloride
No Information Returned
Flupentixol decanoate
No Information Returned
Flupentixol hydrochloride
No Information Returned
Fluphenazine decanoate
No Information Returned
Fluphenazine hydrochloride
No Information Returned
Fluprednidene acetate
No Information Returned
Flurazepam hydrochloride
No Information Returned
Flurbiprofen
No Information Returned
Flurbiprofen sodium
No Information Returned
Flutamide
No Information Returned
Fluticasone furoate
No Information Returned
Fluticasone furoate (Inhalation)
No Information Returned
Fluticasone propionate (Inhalation)
No Information Returned
Fluticasone propionate (Nasal)
No Information Returned
Fluticasone propionate (Topical)
No Information Returned
Fluticasone propionate/azelastine hydrochloride (Nasal)
No Information Returned
Flutrimazole
No Information Returned
02.12.00
Fluvastatin sodium
Lipid modification
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Fluvoxamine maleate
No Information Returned
Folic acid
No Information Returned
Follitropin alfa
No Information Returned
Follitropin alfa and lutropin alfa
No Information Returned
Follitropin beta
No Information Returned
Follitropin delta
No Information Returned
02.08.01
Fondaparinux sodium
VTE prevention post hip/knee replacement
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Caution - potential for latex reactions in allergic patients.
02.08.01
Fondaparinux sodium
Acute coronary syndrome
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Unstable angina and NSTEMI. Caution - potential for latex reactions in allergic patients
09.06.07
Forceval
post Bariatric surgery
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
ONLY after single anastomosis duodenal illeal bypass with sleeve (SADI-S) or duodenal switch surgery
Formaldehyde
No Information Returned
Formoterol fumarate
No Information Returned
Formoterol/glycopyrronium/budesonide
No Information Returned
05.03.01
Fosamprenavir calcium
HIV infection
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
04.06.00
Fosaprepitant
Nausea and vomiting (chemotherapy induced)
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
RSCH Oncology Team only
05.03.02
11.03.03
Foscarnet sodium
Cytomegalovirus
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
05.03.02
11.03.03
Foscarnet sodium
Viral retinitis
Red
Formulations :
  • Intravitreal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Consultant ophthalmologists only
Fosfestrol tetrasodium
No Information Returned
Fosfomycin calcium
No Information Returned
Fosfomycin trometamol
No Information Returned
Fosinopril sodium
No Information Returned
Fosphenytoin sodium
No Information Returned
Fostemsavir
No Information Returned
Framycetin sulfate
No Information Returned
Freeze sprays and gels
No Information Returned
04.07.04
Fremanezumab
Migraine (prevention)
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
04.07.04
Frovatriptan
Migraine (acute)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Not 1st line. Generic sumatriptan, naratriptan, rizatripan, zolmitriptan are preferred.
04.07.04
Frovatriptan
Menstrual related migraine
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label. Use if inadequate response to standard acute migraine treatments
Fructose
No Information Returned
Fuller's earth
No Information Returned
Fulvestrant
No Information Returned
Fumaric acid
No Information Returned
02.02.02
Furosemide
Oedema
Green
Formulations :
  • Injection
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Furosemide/potassium
No Information Returned
Fusafungine
No Information Returned
05.01.07
11.03.01
13.10.01
Fusidic acid
Bacterial eye infection
Green
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
1% modified-release eye drops
05.01.07
11.03.01
13.10.01
Fusidic acid
Bacterial infection
Blue
Formulations :
  • Suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Follow local guidelines on the use of antimicrobials. Use in primary care when indicated by microbiology eg on culture results,
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More